ArticleEuropean radiology2026
Time-efficient MRI scoring system for axial spondyloarthritis: a feasibility study.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop and assess the feasibility of a simplified Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score for quantifying disease activity changes in patients with axial spondyloarthritis (axSpA) undergoing biological therapy, and compare its performance with the original SPARCC score. MATERIALS AND
methodsThis prospective feasibility study included 60 axSpA patients receiving biological therapy. MRI examinations of the sacroiliac joints and spine were performed at baseline and six months after the initiation of biological therapy. The simplified SPARCC score, focusing on the three most affected slices/vertebrae instead of six, was developed and compared with the original SPARCC score. Both scores were correlated with clinical indices and inflammatory markers. Inter-reader agreement and sensitivity to inflammatory changes were evaluated to assess reliability and research utility.
resultsBoth scores showed significant improvement after six months of initiating biological therapy (p < 0.001). The simplified SPARCC scores correlated strongly with disease activity markers, comparable to or stronger than the original scores, with median score reductions of 71.4-79.1%. Inter-reader agreement was substantial to almost perfect for all scores, with simplified SPARCC spine score exhibiting the highest agreement (κ = 0.817 at baseline and 0.784 at follow-up). The simplified score significantly reduced assessment time compared with the original score (11 vs 37 min, p < 0.001).
conclusionThe simplified SPARCC MRI score is a promising research tool for assessing disease activity in axSpA patients, with the advantages of improved inter-reader reliability and significantly reduced assessment time. Further validation is required to confirm its broader clinical applicability. KEY POINTS: Question Can a simplified SPARCC MRI score reduce assessment time while reliably tracking disease activity changes? Findings The simplified SPARCC MRI score showed comparable sensitivity to change and reliability vs the original score, reducing mean assessment time from 37 min to 11 min. Clinical relevance The simplified SPARCC MRI score provides a faster, reliable research method for tracking axSpA activity changes, potentially improving clinical trial efficiency. Further validation is needed to confirm routine clinical utility.
Indexed as
Identifiers
40739054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.